PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Key Inclusion Criteria:

* Patient has a hematological malignancy and is eligible to receive CHOP or R-CHOP regimen.
* Patient must have adequate hematological, renal, and hepatic function as specified below within 30 days prior to the first dose of study treatment:
* Patient has a left ventricular ejection fraction ≥50% by multigated acquisition scan or echocardiogram within 30 days prior to the first dose of study treatment.

Key Exclusion Criteria:

* Patient has severe neurologic disorders (Grade 3 and above) including peripheral motor and sensory, central and autonomic neuropathy.
* Patient has a history of persistent active neurologic disorders including the demyelinating form of Charcot-Marie-Tooth syndrome, acquired demyelinating disorders, and other demyelinating conditions.
* Patient has used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study.
* Patient has bowel obstruction, paralytic ileus, or uncontrolled chronic constipation.
* Patient has severe, active and uncontrolled hepatic disease or dysfunction.